Health
Chemogenetics advances to early human clinical trials in China
Seven early-stage trials are testing synthetic brain receptors activated by low-dose medication to treat epilepsy, Parkinson's disease, and pain.
The short version
- Researchers have begun early human trials of chemogenetics, a method to selectively modulate engineered brain cells using oral drugs.
- Seven trials identified in China involve roughly 10 patients across conditions including epilepsy, Parkinson's disease, and pain.
- The therapy delivers synthetic receptor genes via viral vector brain injections, which are subsequently activated by ultra-low doses of clozapine.
- Trial results remain unknown, with safety monitoring focused on off-target receptor interactions and drug side effects.
Key facts
- Technique co-inventor Bryan Roth disclosed at an August 13 BRAIN Initiative conference that seven chemogenetics clinical trials involving about 10 patients are underway or planned in China.[Hacker News]
- The trials target three neurological conditions: refractory epilepsy, Parkinson's disease, and pain.[Hacker News]
- The experimental treatment uses an adeno-associated virus (AAV) vector injected surgically into targeted brain regions to deliver synthetic receptor genes, primarily hM4Di.[Hacker News]
- Once expressed, the hM4Di synthetic receptors are activated using ultra-low doses of clozapine, such as 3.125 mg in Parkinson's trials compared to standard 300 to 450 mg psychiatric doses.[Hacker News]
What remains uncertain
- Clinical efficacy and safety outcomes from the ongoing human trials have not yet been published or determined.[Hacker News]
- The degree of risk regarding severe clozapine side effects like agranulocytosis at ultra-low dosages remains uncertain and requires long-term patient monitoring.[Hacker News]
- It is unclear if all seven trials exclusively use the hM4Di receptor, as some trial registrations do not disclose the specific designer receptor deployed.[Hacker News]